• sense clinically
  • think mechanistically
  • act interdisciplinarily
  • treat innovatively

Prof. Dr. med. Ulrich Keller

AG Ulrich Keller
Med. Klinik Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie (CBF)
Charité-Universitätsmedizin Berlin
Tibor-Diamantstein-Haus, Haus IB
Hindenburgdamm 30
12203 Berlin

Tel: +49 30 450 513 381
E-Mail: ulrich.keller@ charite.de

 

Scientific Scope

Mechanism-based cancer therapies

Group Members

Team (Charité and TUM)

  • Markus Schick, Postdoc (Charité/TUM)
  • Matthias Wirth, Dr. rer. nat., Postdoc (Charité)
  • Stefan Habringer, Dr. med., Dr. univ., Clinician scientist (Charité)
  • Jolanta Slawska, M.Sc. (TUM)
  • Konstandina Isaakidis, M.Sc. (Charité)
  • Veronika Schulze, M.Sc. (Charité)
  • Stefanos Alexandros Bamopoulos, Clinician scientist (Charité)
  • Nikita Nikita, PhD student (Charité)
  • Le Zhang, MD student (Charité)
  • Minh Ho, Technical assistant (Charité)
  • Yingfen Hong, MD student (TUM/Charité)
  • Josefina Doffo, PhD student (Charité)
  • Elena Rohleder, Dr. med., Clinician scientist (Charité)
  • Sven Liebig, Clinician scientist (Charité)
  • Francis Baumgartner, Dr. med., Clinician scientist (Charité)
  • Uta Demel, Dr. med., Clinician scientist (Charité)
  • Richard Lewis, MD student (TUM/Charité)
  • Stavroula Litsiou, Phd student (Charité/FU)
  • Laura Schmalbrock, Dr. med., Clinician scientist (Charité)

Selected References

  • Biederstädt A, Hassan Z, Schneeweis C, Schick M, Schneider L, Muckenhuber A, Hong Y, Siegers G, Nilsson L, Wirth M, Dantes Z, Steiger K, Schunck K, Langston S, Lenhof HP, Coluccio A, Orben F, Slawska J, Scherger A, Saur D, Müller S, Rad R, Weichert W, Nilsson J, Reichert M, Schneider G, Keller U. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Gut. 2020
  • O'Connor T, Zhou X, Kosla J, Adili A, Garcia Beccaria M, Kotsiliti E, Pfister D, Johlke AL, Sinha A, Sankowski R, Schick M, Lewis R, Dokalis N, Seubert B, Höchst B, Inverso D, Heide D, Zhang W, Weihrich P, Manske K, Wohlleber D, Anton M, Hoellein A, Seleznik G, Bremer J, Bleul S, Augustin HG, Scherer F, Koedel U, Weber A, Protzer U, Förster R, Wirth T, Aguzzi A, Meissner F, Prinz M, Baumann B, Höpken UE, Knolle PA, von Baumgarten L, Keller U, Heikenwälder M. Age-related Gliosis Promotes Central Nervous System Lymphoma through CCL19-mediated Tumor Cell Retention. Cancer Cell. 2019
  • Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Lückerath K, Pietschmann E, Habringer S, Gerngroß C, Franke K, Rudelius M, Schirbel A, Lapa C, Schwamborn K, Steidle S, Hartmann E, Rosenwald A, Kropf S, Beer AJ, Peschel C, Einsele H, Buck AK, Schwaiger M, Götze K, Wester HJ, Keller U. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med. 2015
  • Dechow T, Steidle S, Götze KS, Rudelius M, Behnke K, Pechloff K, Kratzat S, Bullinger L, Fend F, Soberon V, Mitova N, Li Z, Thaler M, Bauer J, Pietschmann E, Albers C, Grundler R, Schmidt-Supprian M, Ruland J, Peschel C, Duyster J, Rose-John S, Bassermann F, Keller U. GP130 activation induces myeloma and collaborates with MYC. J Clin Invest. 2014
  • Hoellein A, Fallahi M, Schoeffmann S, Steidle S, Schaub FX, Rudelius M, Laitinen I, Nilsson L, Goga A, Peschel C, Nilsson JA, Cleveland JL, Keller U. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. Blood. 2014